| Conditions: |
|
Breast Cancer - Colon Cancer - Prostate Cancer - Lung Cancer |
| Purpose: |
|
The basic premise of this research proposal is to determine whether there is any significant
association between germline polymorphisms and cancers of colon, breast, testicular,
prostate, lung, lymphoid organs, and head and neck. This is an exploratory study designed to
generate hypotheses for further research.
|
| Study Summary: |
|
To establish significant correlations between genetic polymorphisms and cancer, a
largescale, systematic comparison of genetic alterations utilizing a case-control
methodology is proposed. To date, such studies have been limited due to the large number of
samples necessary for obtaining statistical significance, and the lack of rapid and accurate
methods to screen for genetic polymorphisms. We propose to utilize an anonymized design to
obtain DNA from residual material from routine diagnostic blood tests, to link these samples
to a limited set of clinical variables, and to test for the frequency of candidate
low-penetrance cancer susceptibility alleles. These data will be combined with similar data
from a control group of age- and ethnically-matched volunteers for a related cohort study to
be conducted separately. Polymorphisms to be screened for include those involving the genes
PTEN, APC, TGF βR-I, BLM, CHK2, a p85 phosphoprotein, ATM, ER, PR, MCP-1, MPIF, CCR2/5,
CCR3, and SULT1A1. Cancers to be included are breast, colon, testicular, lung, prostate,
lymphoid neoplasms, and head and neck carcinomas. Genes with SNPs known to be relevant for
either the development or treatment of lymphoid malignancies will also be targeted.
Specifically, candidate genes will be selected from 1) cytokine signaling, 2) DNA repair,
and 3) apoptosis regulatory pathways.
|
| Criteria: |
|
Inclusion Criteria:
- Patients with a histologic diagnosis of cancer of the colon, breast, testicles,
lungs, prostate, head and neck, or lymphoid organs, who have donated a diagnostic
blood sample as either an inpatient or outpatient at MSKCC.
- All patients who have two or more histologic diagnoses of the same primary tumor type
involving the above sites.
- Patients of Ashkenazi Jewish ancestry with a histologic diagnosis of cancer of any
type.
- Samples ascertained as part of protocol 98-024A(1) are also eligible for
ascertainment in this study.
Exclusion Criteria:
- MSKCC patients without a histologic diagnosis of cancer of the breast, colon,
testicles, lungs, prostate, or lymphoid malignancy (including all types of lymphoma)
will not be eligible for the AMDeC sponsored component of the study.
|
| NCT ID: |
|
NCT00579514 |
| Primary Contact: |
|
Principal Investigator
Kenneth Offit, MD
Memorial Sloan-Kettering Cancer Center
Kenneth Offit, MD
Phone: 646-888-4067
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
New York, New York 10065
United States
There is no listed contact information for this specific location.
Site Status: Recruiting |